These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25412610)

  • 21. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
    J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-kappaB ligand in osteoblasts.
    Chen JR; Haley RL; Hidestrand M; Shankar K; Liu X; Lumpkin CK; Simpson PM; Badger TM; Ronis MJ
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1182-90. PubMed ID: 16971503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RANKL/RANK - from bone physiology to breast cancer.
    Sigl V; Penninger JM
    Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.
    Schramek D; Leibbrandt A; Sigl V; Kenner L; Pospisilik JA; Lee HJ; Hanada R; Joshi PA; Aliprantis A; Glimcher L; Pasparakis M; Khokha R; Ormandy CJ; Widschwendter M; Schett G; Penninger JM
    Nature; 2010 Nov; 468(7320):98-102. PubMed ID: 20881962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of inflammatory cascade is implicated in methyl amooranin-mediated inhibition of experimental mammary carcinogenesis.
    Mandal A; Bhatia D; Bishayee A
    Mol Carcinog; 2014 Dec; 53(12):999-1010. PubMed ID: 23846978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase.
    Hu H; Wang J; Gupta A; Shidfar A; Branstetter D; Lee O; Ivancic D; Sullivan M; Chatterton RT; Dougall WC; Khan SA
    Breast Cancer Res Treat; 2014 Aug; 146(3):515-23. PubMed ID: 25007964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro effects of erythromycin on RANKL and nuclear factor-kappa B by human TNF-alpha stimulated Jurkat cells.
    Wu L; Lin JH; Bao K; Li PF; Zhang WG
    Int Immunopharmacol; 2009 Aug; 9(9):1105-9. PubMed ID: 19500694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors.
    Sugatani T; Alvarez UM; Hruska KA
    J Cell Biochem; 2003 Sep; 90(1):59-67. PubMed ID: 12938156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cynomorium songaricum prevents bone resorption in ovariectomized rats through RANKL/RANK/TRAF6 mediated suppression of PI3K/AKT and NF-κB pathways.
    Ma X; Liu J; Yang L; Zhang B; Dong Y; Zhao Q
    Life Sci; 2018 Sep; 209():140-148. PubMed ID: 30092296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
    Schramek D; Sigl V; Penninger JM
    Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism.
    Bava SV; Sreekanth CN; Thulasidasan AK; Anto NP; Cheriyan VT; Puliyappadamba VT; Menon SG; Ravichandran SD; Anto RJ
    Int J Biochem Cell Biol; 2011 Mar; 43(3):331-41. PubMed ID: 20883815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB.
    Pozo-Guisado E; Merino JM; Mulero-Navarro S; Lorenzo-Benayas MJ; Centeno F; Alvarez-Barrientos A; Fernandez-Salguero PM
    Int J Cancer; 2005 May; 115(1):74-84. PubMed ID: 15688415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
    McGonigle JS; Giachelli CM; Scatena M
    Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.